The androgen receptor and its use in biological assays: Looking toward effect-based testing and its applications

Journal of Analytical Toxicology

Volumn 35, Issue 9, 2011, Pages 594-607

  Cadwallader, Amy B ^a   Lim, Carol S ^b   Rollins, Douglas E ^b   Botrè, Francesco ^a,c  

^a Laboratorio Antidoping   (Italy)

^b UNIVERSITY OF UTAH   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN RECEPTOR; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR COREPRESSOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; STEROID; STEROID RECEPTOR; TESTOSTERONE;

ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CELL ASSAY; CELL STRAIN COS7; CHROMATOGRAPHY; DOPING; DRUG DETERMINATION; DRUG EXPOSURE; DRUG IDENTIFICATION; HUMAN; INTERMETHOD COMPARISON; MASS SPECTROMETRY; STEROID METABOLISM;

ANABOLIC AGENTS; BIOLOGICAL ASSAY; DOPING IN SPORTS; HUMANS; LIGANDS; PERFORMANCE-ENHANCING SUBSTANCES; PROTEIN BINDING; RECEPTORS, ANDROGEN; SUBSTANCE ABUSE DETECTION;

EID: 82855182139     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/anatox/35.9.594     Document Type: Article

References (135)

1. O. Barroso, I. Mazzoni, and O. Rabin. Hormone abuse in sports: the antidoping perspective. Asian J.Androl. 10: 391-402 (2008).
2. F. Botrè. New and old challenges of sports drug testing. J.Mass. Spectrom. 43: 903-907 (2008).
3. WADA. The 2009 WADA Prohibited List. http://www.wadaama.org/rtecontent/document/2008_List_En.pdf (accessed April 2011).
4. WADA. The 2009 WADA Laboratory Statistics. http://www.wada-ama.org/Documents/Science_Medicine/Anti-Doping_Laboratories/Lab_Statistics/WADA_2009_LaboratoryStatisticsReport_Final.pdf (accessed April 2011).
5. F. Hartgens and H. Kuipers. Effects of androgenic-anabolic steroids in athletes. Sports Med. 34: 513-554 (2004).
6. C. Kuhn. Anabolic steroids. Recent Prog. Horm. Res. 57: 411-434 (2002).
7. I. Thiblin and A. Petersson. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam. Clin. Pharmacol. 19: 27-44 (2005).
8. N.T. Shahidi. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther. 23: 1355-1390 (2001).
9. D.H. Catlin, M.H. Sekera, B.D. Ahrens, B. Starcevic,Y.C. Chang, and C.K. Hatton. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 18: 1245-1049 (2004).
10. FDA warning on unapproved performance enhancer. FDA Consum. 38: 4 (2004).
11. S. Ashley. Doping by design. Sci. Am. 290: 22-23 (2004).
12. J. Knight. Drugs in sport: no dope. Nature 426: 114-115 (2003).
13. W. Kondro. Athletes' "designer steroid" leads to widening scandal. Lancet 362: 1466 (2003).
14. C.G. Georgakopoulos, A. Vonaparti, M. Stamou, P. Kiousi, E. Lyris,Y.S. Angelis, G. Tsoupras, B.Wuest, M.W. Nielen, I. Panderi, and M. Koupparis. Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun. Mass Spectrom. 21: 2439-2446 (2007).
15. A. Vonaparti, E. Lyris, Y.S. Angelis, I. Panderi, M. Koupparis, A. Tsantili-Kakoulidou, R.J. Peters, M.W. Nielen, and C. Georgakopoulos. Preventive doping control screening analysis of prohibited substances in human urine using rapid-resolution liquid chromatography/high-resolution time-of-flight mass spectrometry. Rapid Commun.Mass Spectrom. 24: 1595-1609 (2010).
16. O.J. Pozo, K. Deventer, P.VanEenoo, and F.T. Delbeke. Efficient approach for the comprehensive detection of unknown anabolic steroids and metabolites in human urine by liquid chromatography-electrospray-tandem mass spectrometry. Anal. Chem. 80: 709-720 (2008).
17. M.J. Tsai and B.W. O'Malley. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63: 451-486 (1994).
18. L.P. Freedman. Molecular Biology of Steroid and Nuclear Hormone Receptors. Birkhäuser, Boston, MA, 1998.
19. C.S. Chang, J. Kokontis, and S.T. Liao. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc. Natl. Acad. Sci. USA 85: 7211-7215 (1988).
20. C.S. Chang, J. Kokontis, and S.T. Liao. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240: 324-326 (1988).
21. W. Gao, C.E. Bohl, and J.T. Dalton. Chemistry and structural biology of androgen receptor. Chem. Rev. 105: 3352-3370 (2005).
22. A.O. Brinkmann. Lessons to be learned from the androgen receptor. Eur. J. Dermatol. 11: 301-303 (2001).
23. F. Claessens, S. Denayer, N.Van Tilborgh, S. Kerkhofs, C. Helsen, and A. Haelens. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal 6: e008 (2008).
24. W.B. Pratt and D.O. Toft. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18: 306-360 (1997).
25. B.S.Warren, P. Kusk, R.G.Wolford, and G.L. Hager. Purification and stabilization of transcriptionally active glucocorticoid receptor. J. Biol. Chem. 271: 11434-11440 (1996).
26. J. Li and F. Al-Azzawi. Mechanism of androgen receptor action. Maturitas 63: 142-148 (2009).
27. M.K. Dahmer, M.W. Quasney, S.T. Bissen, and W.B. Pratt. Molybdate permits resolution of untransformed glucocorticoid receptors from the transformed state. J. Biol. Chem. 256: 9401-9405 (1981).
28. J.R. Davis, M. Kakar, and C.S. Lim. Controlling protein compartmentalization to overcome disease. Pharm. Res. 24: 17-27 (2007).
29. D. Gorlich and U. Kutay. Transport between the cell nucleus and the cytoplasm. Annu. Rev. Cell Dev. Biol. 15: 607-660 (1999).
30. G. Jenster, T.E. Spencer, M.M. Burcin, S.Y. Tsai, M.-J. Tsai, and B.W. O'Malley. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. USA 94: 7879-7884 (1997).
31. P.M. Holterhus, S. Piefke, and O. Hiort. Anabolic steroids, testosterone-precursors and virilizing androgens induce distinct activation profiles of androgen responsive promoter constructs. J. Steroid Biochem. Mol. Biol. 82: 269-275 (2002).
32. G.G. Prefontaine, M.E. Lemieux, W. Giffin, C. Schild-Poulter, L. Pope, E. LaCasse, P. Walker, and R.J.G. Hache. Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol. Cell. Biol. 18: 3416-3430 (1998).
33. M. Truss and M. Beato. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr. Rev. 14: 459-479 (1993).
34. A.B. Cadwallader, D.E. Rollins, and C.S. Lim. Effect of anabolicandrogenic steroids and glucocorticoids on the kinetics of hAR and hGR nucleocytoplasmic translocation. Mol. Pharm. 7: 689-698 (2010).
35. NURSA. Tissue-specific expression patterns of nuclear receptors, Androgen Receptor. http://www.nursa.org/10.1621/datasets.02001 (accessed April 2011).
36. S. Bhasin, W.E. Taylor, R. Singh, J. Artaza, I. Sinha-Hikim, R. Jasuja, H. Choi, and N.F. Gonzalez-Cadavid. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J. Gerontol. A Biol. Sci. Med. Sci. 58: M1103-1110 (2003).
37. J.C. Chen and D.J. Goldhamer. Skeletal muscle stem cells. Reprod. Biol. Endocrinol. 1: 101 (2003) http://www.rbej.com/content/1/1/101.
38. K.L. Herbst and S. Bhasin. Testosterone action on skeletal muscle. Curr.Opin. Clin. Nutr.Metab. Care 7: 271-277 (2004).
39. I. Sinha-Hikim,W.E. Taylor, N.F. Gonzalez-Cadavid,W. Zheng, and S. Bhasin. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J. Clin. Endocrinol. Metab. 89: 5245-5255 (2004).
40. I. Sinha-Hikim, J. Artaza, L.Woodhouse, N. Gonzalez-Cadavid, A.B. Singh, M.I. Lee, T.W. Storer, R. Casaburi, R. Shen, and S. Bhasin. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol. Metab. 283: E154-164 (2002).
41. R. Singh, J.N. Artaza,W.E. Taylor, M. Braga, X. Yuan, N.F. Gonzalez-Cadavid, and S. Bhasin. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonicalWnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147: 141-154 (2006).
42. R. Singh, J.N. Artaza, W.E. Taylor, N.F. Gonzalez-Cadavid, and S. Bhasin. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144: 5081-5088 (2003).
43. K. Choong, K.M. Lakshman, and S. Bhasin. The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. Asian J. Androl. 10: 351-363 (2008).
44. Y. Chen, J.D. Zajac, and H.E. MacLean. Androgen regulation of satellite cell function. J. Endocrinol. 186: 21-31 (2005).
45. Y. Joubert and C. Tobin. Satellite cell proliferation and increase in the number ofmyonuclei induced by testosterone in the levator ani muscle of the adult female rat. Dev. Biol. 131: 550-557 (1989).
46. I. Sinha-Hikim, S.M. Roth, M.I. Lee, and S. Bhasin. Testosteroneinduced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am. J. Physiol. Endocrinol. Metab. 285: E197-E205 (2003).
47. M. Doumit, D.R. Cook, and R.A. Merkel. Testosterone up-regulates androgen receptors and decreases differentiation of porcine myogenic satellite cells in vitro. Endocrinology 137: 1385-1394 (1996).
48. H.V. Heemers and D.J. Tindall. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28: 778-808 (2007).
49. K.W. Nettles and G.L. Greene. Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 67: 309-333 (2005).
50. X. Gao, B.W. Loggie, and Z. Nawaz. The roles of sex steroid receptor coregulators in cancer. Mol. Cancer 1: 1-7 (2002).
51. K. Pereira de Jesus-Tran, P.L. Cote, L. Cantin, J. Blanchet, F. Labrie, and R. Breton. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 15: 987-999 (2006).
52. A. Stevens, H. Garside, A. Berry, C. Waters, A. White, and D. Ray. Dissociation of steroid receptor coactivator 1 and nuclear receptor corepressor recruitment to the human glucocorticoid receptor by modification of the ligand-receptor interface: the role of tyrosine 735. Mol. Endocrinol. 17: 845-859 (2003).
53. B.D. Darimont, R.L. Wagner, J.W. Apriletti, M.R. Stallcup, P.J. Kushner, J.D. Baxter, R.J. Fletterick, and K.R. Yamamoto. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12: 3343-3356 (1998).
54. E. Estebanez-Perpina, J.M. Moore, E. Mar, E. Delgado-Rodrigues, P. Nguyen, J.D. Baxter, B.M. Buehrer, P. Webb, R.J. Fletterick, and R.K. Guy. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J. Biol. Chem. 280: 8060-8068 (2005).
55. E. Hur, S.J. Pfaff, E.S. Payne, H. Grøn, B.M. Buehrer, and R.J. Fletterick. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol. 2: E274 (2004).
56. C.A. Heinlein and C. Chang. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23: 175-200 (2002).
57. S.S. Nussey and S.A.Whitehead. Endocrinology: An Integrated Approach. BIOS Scientific Publishers, Oxford, U.K., 2001.
58. P. Snyder. Androgens. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., J.G. Hardman, L.E. Limbird, and A.G. Gilman, Eds. McGraw-Hill, New York, NY, 2001, pp 1635-1648.
59. W. Schanzer. Metabolism of anabolic androgenic steroids. Clin. Chem. 42: 1001-1020 (1996).
60. R. Hickson, S. Czerwinski, M. Falduto, and A. Young. Glucocorticoid antagonism by exercise and androgenic-anabolic steroids. Med. Sci. Sports Exerc. 22: 331-340 (1990).
61. R.C. Hickson and J.R. Marone. Exercise and inhibition of glucocorticoid-induced muscle atrophy. Exerc. Sport Sci. Rev. 21: 135-167 (1993).
62. M. Mayer and F. Rosen. Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. Am. J. Physiol. 229: 1381-1386 (1975).
63. R.W. Brueggemeier. Sex Hormones (Male): Analogs and Antagonists. Wiley,Weinheim, Germany, 2006.
64. D.J. Handelsman and A. Heather. Androgen abuse in sports. Asian J. Androl. 10: 403-415 (2008).
65. J.A.Vida. Androgens and Anabolic Agents: Chemistry and Pharmacology. Academic Press, NewYork, NY, 1969.
66. http://anabolicminds.com/forum/steroids/9989-vida-textandrogens. html (accessed June 2010).
67. http://www.demonoid.com/files/details/1643294/008522825736/(accessed June 2010).
68. A.T. Kicman. Pharmacology of anabolic steroids. Br. J. Pharmacol. 154: 502-521 (2008).
69. M.L. Mohler, C.E. Bohl, A. Jones, C.C. Coss, R. Narayanan, Y. He, D.J. Hwang, J.T. Dalton, and D.D. Miller. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 52: 3597-3617 (2009).
70. J.T. Dalton, A. Mukherjee, Z. Zhu, L. Kirkovsky, and D.D. Miller. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. 244: 1-4 (1998).
71. R. Narayanan, M.L. Mohler, C.E. Bohl, D.D. Miller, and J.T. Dalton. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signal 6: e010 (2008).
72. J.D. Kearbey, D.Wu,W. Gao, D.D. Miller, and J.T. Dalton. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica 34: 273-280 (2004).
73. J. Chen, J. Kim, and J.T. Dalton. Discovery and therapeutic promise of selective androgen receptor modulators. Mol. Interv. 5: 173-188 (2005).
74. M. Thevis and W. Schänzer. Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb. Exp. Pharmacol. 195: 99-126 (2010).
75. C.Y. Chang and D.P. McDonnell. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol. Sci. 26: 225-228 (2005).
76. WADA. TheWorld Anti-Doping Code. The 2010 Prohibited List. International Standard.WADA, Montreal, QC, Canada, 2010.
77. M. Thevis and W. Schanzer. Mass spectrometry of selective androgen receptor modulators. J. Mass Spectrom. 43: 865-876 (2008).
78. T. Kuuranne, A. Leinonen, W. Schanzer, M. Kamber, R. Kostiainen, and M. Thevis. Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metab. Dispos. 36: 571-581 (2008).
79. M. Thevis, M. Kohler, A. Thomas, J. Maurer, N. Schlorer, M. Kamber, and W. Schanzer. Determination of benzimidazoleand bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. Anal. Bioanal. Chem. 391: 251-261 (2008).
80. M. Thevis, A. Thomas, M. Kohler, S. Beuck, and W. Schanzer. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J.Mass Spectrom. 44: 442-460 (2009).
81. M. Thevis and W. Schanzer. Illicit organogenesis: methods and substances of doping and manipulation. Organogenesis 4: 264-271 (2008).
82. M. Thevis, M. Kohler, and W. Schanzer. New drugs and methods of doping and manipulation. Drug Discov. Today 13: 59-66 (2008).
83. C.R. Borges, N. Miller, M. Shelby, M. Hansen, C. White, M.H. Slawson, K. Monti, and D.J. Crouch. Analysis of a challenging subset of World Anti-Doping Agency-banned steroids and antiestrogens by LC-MS-MS. J. Anal. Toxicol. 31: 125-131 (2007).
84. M. Kolmonen, A. Leinonen, A. Pelander, and I. Ojanperä. A general screening method for doping agents in human urine by solid phase extraction and liquid chromatography/time-of-flight mass spectrometry. Anal. Chim. Acta 585: 94-102 (2007).
85. M. Mazzarino, M. Orengia, and F. Botre. Application of fast gas chromatography/mass spectrometry for the rapid screening of synthetic anabolic steroids and other drugs in anti-doping analysis. Rapid Commun. Mass Spectrom. 21: 4117-4124 (2007).
86. O.J. Pozo, P. Van Eenoo, K. Deventer, and F.T. Delbeke. Development and validation of a qualitative screening method for the detection of exogenous anabolic steroids in urine by liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 389: 1209-1224 (2007).
87. P. Roy, M. Alevizaki, and I. Huhtaniemi. In vitro bioassays for androgens and their diagnostic applications. Hum. Reprod.Update 14: 73-82 (2008).
88. T.F. Bovee, G. Bor, H.H. Heskamp, J.J. Lasaroms, M.B. Sanders, and M.W. Nielen. Validation and application of a yeast bioassay for screening androgenic activity in calf urine and feed. Anal. Chim. Acta 637: 225-234 (2009).
89. T.F. Bovee, R.J. Helsdingen, A.R. Hamers, M.B. van Duursen, M.W. Nielen, and R.L. Hoogenboom. A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists. Anal. Bioanal. Chem. 389: 1549-1558 (2007).
90. T.F. Bovee, M. Thevis, A.R. Hamers, A.A. Peijnenburg, M.W. Nielen, and W.G. Schoonen. SERMs and SARMs: detection of their activities with yeast based bioassays. J. Steroid Biochem. Mol. Biol. 118: 85-92 (2009).
91. K.W. Gaido, L.S. Leonard, S. Lovell, J.C. Gould, D. Babai, C.J. Portier, and D.P. McDonnell. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol. Appl. Pharmacol. 143: 205-212 (1997).
92. H.J. Lee, Y.S. Lee, H.B. Kwon, and K. Lee. Novel yeast bioassay system for detection of androgenic and antiandrogenic compounds. Toxicol. In Vitro 17: 237-244 (2003).
93. P. Leskinen, E. Michelini, D. Picard, M. Karp, and M.Virta. Bioluminescent yeast assays for detecting estrogenic and androgenic activity in different matrices. Chemosphere 61: 259-266 (2005).
94. P. Mak, F.D. Cruz, and S. Chen. A yeast screen system for aromatase inhibitors and ligands for androgen receptor: yeast cells transformed with aromatase and androgen receptor. Environ. Health Perspect. 107: 855-860 (1999).
95. E. Michelini, P. Leskinen, M.Virta, M. Karp, and A. Roda. A new recombinant cell-based bioluminescent assay for sensitive androgen-like compound detection. Biosens. Bioelectron. 20: 2261-2267 (2005).
96. E. Michelini, M. Magliulo, P. Leskinen, M. Virta, M. Karp, and A. Roda. Recombinant cell-based bioluminescence assay for androgen bioactivity determination in clinical samples. Clin. Chem. 51: 1995-1998 (2005).
97. I.J. Purvis, D. Chotai, C.W. Dykes, D.B. Lubahn, F.S. French, E.M. Wilson, and A.N. Hobden. An androgen-inducible expression system for Saccharomyces cerevisiae. Gene 106: 35-42 (1991).
98. P. Sohoni and J.P. Sumpter. Several environmental oestrogens are also anti-androgens. J. Endocrinol. 158: 327-339 (1998).
99. O. Zierau, S. Lehmann, G. Vollmer, W. Schanzer, and P. Diel. Detection of anabolic steroid abuse using a yeast transactivation system. Steroids 73: 1143-1147 (2008).
100. V. Beck, E. Reiter, and A. Jungbauer. Androgen receptor transactivation assay using green fluorescent protein as a reporter. Anal. Biochem. 373: 263-271 (2008).
101. B.M. Blankvoort, E.M. de Groene, A.P. van Meeteren-Kreikamp, R.F.Witkamp, R.J. Rodenburg, and J.M. Aarts. Development of an androgen reporter gene assay (AR-LUX) utilizing a human cell line with an endogenously regulated androgen receptor. Anal. Biochem. 298: 93-102 (2001).
102. J. Chen, M.R. Sowers, F.M. Moran, D.S. McConnell, N.A. Gee, G.A. Greendale, C. Whitehead, S.E. Kasim-Karakas, and B.L. Lasley. Circulating bioactive androgens in midlife women. J. Clin. Endocrinol. Metab. 91: 4387-4394 (2006).
103. M.E. de Gooyer, H.M. Oppers-Tiemissen, D. Leysen, H.A. Verheul, and H.J. Kloosterboer. Tibolone is not converted by human aromatase to 7alpha-methyl-17alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 68: 235-243 (2003).
104. C.J. Houtman, S.S. Sterk, M.P. van de Heijning, A. Brouwer, R.W. Stephany, B. van der Burg, and E. Sonneveld. Detection of anabolic androgenic steroid abuse in doping control using mammalian reporter gene bioassays. Anal. Chim. Acta 637: 247-258 (2009).
105. W. Mnif, S. Dagnino, A. Escande, A. Pillon, H. Fenet, E. Gomez, C. Casellas, M.J. Duchesne, G. Hernandez-Raquet,V. Cavaillès, P. Balaguer, and A. Bartegi. Biological analysis of endocrine-disrupting compounds in Tunisian sewage treatment plants. Arch. Environ. Contam. Toxicol. 59(1): 1-12 (2010).
106. F. Paris, F. Rabeolina, P. Balaguer, A. Bacquet, and C. Sultan. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line. Gynecol. Endocrinol. 23: 193-197 (2007).
107. F. Paris, N. Servant, B. Terouanne, P. Balaguer, J.C. Nicolas, and C. Sultan. A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children. J. Clin. Endocrinol. Metab. 87: 791-797 (2002).
108. F. Paris, N. Servant, B. Terouanne, and C. Sultan. Evaluation of androgenic bioactivity in human serum by recombinant cell line: preliminary results. Mol. Cell Endocrinol. 198: 123-129 (2002).
109. T. Raivio, J.J. Palvimo, L. Dunkel, S.Wickman, and O.A. Janne. Novel assay for determination of androgen bioactivity in human serum. J. Clin. Endocrinol. Metab. 86: 1539-1544 (2001).
110. P. Roy, S. Franks, M. Read, and I.T. Huhtaniemi. Determination of androgen bioactivity in human serum samples using a recombinant cell based in vitro bioassay. J. Steroid Biochem.Mol. Biol. 101: 68-77 (2006).
111. P. Roy, H. Salminen, P. Koskimies, J. Simola, A. Smeds, P. Saukko, and I.T. Huhtaniemi. Screening of some anti-androgenic endocrine disruptors using a recombinant cell-based in vitro bioassay. J. Steroid Biochem.Mol. Biol. 88: 157-166 (2004).
112. E. Sonneveld, H.J. Jansen, J.A. Riteco, A. Brouwer and B. van der Burg. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol. Sci. 83: 136-148 (2005).
113. E. Sonneveld, J.A. Riteco, H.J. Jansen, B. Pieterse, A. Brouwer, W.G. Schoonen, and B. van der Burg. Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities. Toxicol. Sci. 89: 173-187 (2006).
114. B. Terouanne, P. Nirdé, F. Rabenoelina,W. Bourguet, C. Sultan, and G. Auzou. Mutation of the androgen receptor at amino acid 708 (Gly-->Ala) abolishes partial agonist activity of steroidal antiandrogens. Mol. Pharmacol. 63: 791-798 (2003).
115. A.T. Szafran, M. Szwarc, M. Marcelli, and M.A. Mancini. Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One 3: e3605 (2008).
116. E. Denolet, K.D. Gendt, J.V. Swinnen, G. Verrijdt, L. Deboel, T. Roskams, and G. Verhoeven. Transfection with steroid-responsive reporter constructs shows glucocorticoid rather than androgen responsiveness in cultured Sertoli cells. J. Steroid Biochem. Mol. Biol. 98: 164-173 (2006).
117. V.S. Wilson, K. Bobseine, C.R. Lambright, and L.E. Gray, Jr. A novel cell line, MDA-kb2, that stably expresses an androgenand glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol. Sci. 66: 69-81 (2002).
118. D. Zuccarello, A. Ferlin, C. Vinanzi, E. Prana, A. Garolla, L. Callewaert, F. Claessens, A.O. Brinkmann, and C. Foresta. Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility. Clin. Endocrinol. (Oxf.) 68: 580-588 (2008).
119. F. Claessens, P. Alen, A. Devos, B. Peeters, G. Verhoeven, and W. Rombauts. The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. J. Biol. Chem. 271: 19013-19016 (1996).
120. F. Claessens, G. Verrijdt, E. Schoenmakers, A. Haelens, B. Peeters, G. Verhoeven and W. Rombauts. Selective DNA binding by the androgen receptor as a mechanism for hormonespecific gene regulation. J. Steroid Biochem. Mol. Biol. 76: 23-30 (2001).
121. E. Schoenmakers, G. Verrijdt, B. Peeters, G. Verhoeven, W. Rombauts, and F. Claessens. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses. J. Biol. Chem. 275: 12290-12297 (2000).
122. G. Verrijdt, E. Schoenmakers, P. Alen, A. Haelens, B. Peeters, W. Rombauts, and F. Claessens. Androgen specificity of a response unit upstream of the human secretory component gene is mediated by differential receptor binding to an essential androgen response element. Mol. Endocrinol. 13: 1558-1570 (1999).
123. G. Verrijdt, E. Schoenmakers, A. Haelens, B. Peeters, G. Verhoeven, W. Rombauts, and F. Claessens. Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J. Biol. Chem. 275: 12298-12305 (2000).
124. P. Maruvada, C.T. Baumann, G.L. Hager, and P.M. Yen. Dynamic shuttling and intranuclear mobility of nuclear hormone receptors. J. Biol. Chem. 278: 12425-12432 (2003).
125. M.J. Schaaf and J.A. Cidlowski. Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity. Mol. Cell Biol. 23: 1922-1934 (2003).
126. C.M. Klinge, S.C. Jernigan, K.A. Mattingly, K.E. Risinger, and J. Zhang. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J. Mol. Endocrinol. 33: 387-410 (2004).
127. J.D. Norris, L.A. Paige, D.J. Christensen, C.Y. Chang, M.R. Huacani, D. Fan, P.T. Hamilton, D.M. Fowlkes, and D.P. McDonnell. Peptide antagonists of the human estrogen receptor. Science 285: 744-746 (1999).
128. J. Zhang, X. Hu, and M.A. Lazar. A novel role for helix 12 of retinoid X receptor in regulating repression. Mol. Cell Biol. 19: 6448-6457 (1999).
129. O. Shen, G. Du, H. Sun,W.Wu, Y. Jiang, L. Song, and X.Wang. Comparison of in vitro hormone activities of selected phthalates using reporter gene assays. Toxicol. Lett. 191: 9-14 (2009).
130. A.J. Saporita, Q. Zhang, N. Navai, Z. Dincer, J. Hahn, X. Cai, and Z.Wang. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J. Biol. Chem. 278: 41998-42005 (2003).
131. C. Massaad, M. Garlatti, E.M. Wilson, F. Cadepond, and R. Barouki. A natural sequence consisting of overlapping glucocorticoid-responsive elements mediates glucocorticoid, but not androgen, regulation of gene expression. Biochem. J. 350 Pt 1: 123-129 (2000).
132. A. Escande, N. Servant, F. Rabenoelina, G. Auzou, H. Kloosterboer, V. Cavailles, P. Balaguer, and T. Maudelonde. Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J. Steroid Biochem.Mol. Biol. 116: 8-14 (2009).
133. O. Zierau, C. Morrissey, R.W. Watson, P. Schwab, S. Kolba, P. Metz, and G. Vollmer. Antiandrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin. Planta Med. 69: 856-858 (2003).
134. B. Terouanne, B. Tahiri, V. Georget, C. Belon, N. Poujol, C. Avances, F. Orio, Jr., P. Balaguer, and C. Sultan. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol. Cell Endocrinol. 160: 39-49 (2000).
135. B.P. Schimmer and K.L. Parker. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., J.G. Hardman, L.E. Limbird, and A.G. Gilman, Eds. McGraw-Hill, New York, NY, 2001, pp 1649-1677.